Animal Models of Human Retinal Dystrophies Sequence Differences in the Coding Region of the Genes for Offer Many Obvious Benefits

Total Page:16

File Type:pdf, Size:1020Kb

Animal Models of Human Retinal Dystrophies Sequence Differences in the Coding Region of the Genes for Offer Many Obvious Benefits Animal models of SIMON M. PETERSEN-JONES human retinal dystrophies Abstract retinal dystrophies in man occur as part of multi system diseases or syndromes such as Usher's Naturally occurring retinal dystrophies in syndrome and Norrie disease. There are animal laboratory and companion animals represent a models with similar multi-system involvement, wealth of different conditions, some of which one example being the tubby mouse (tub) that are important from a comparative point of develops a syndromic disease characterised by view, and all of which offer opportunities to retinal and cochlear degeneration as well as further the understanding of retinal function adult-onset obesity with insulin resistance and and reaction in health and disease. The study impaired glucose tolerance.1 Identification of of animal models of retinal dystrophies has the tub gene led to the recognition of a new provided candidate genes for investigation in family of genes, the human homologues of conditions of man such as retinitis pigmentosa which are potential candidates for retinal and has also led to the identification of new dystrophies? There are still several naturally genes and even new families of genes. occurring mouse models of retinal dystrophy Mutations in the gene for the beta subunit of that await molecular characterisation and may cyclic GMP phosphodiesterase cause retinal provide new candidate genes for human disease dystrophies in man, mice and dog, and or, as was the case with the tubby mouse, lead mutations in the gene for the structural protein to the identification of new families of genes. In peripherin/RDS result in a retinal dystrophy addition to the spontaneous dystrophies the in the mouse and a spectrum of differing laboratory mouse offers the opportunity for retinal dystrophies in man. Animals with genetic manipulation either by the introduction homologous retinal dystrophies to man may of a foreign gene (to create a transgenic animal) make useful models for investigation of treatment either by drugs or by gene therapy. or by the targeted disruption of an endogenous Furthermore the use of transgenics and gene gene (gene 'knock-out'). These techniques are targeting in laboratory mice offers the powerful tools for the investigation of the opportunity to create new models of human retinal dystrophies as well as other diseases. retinal dystrophies and also to investigate the Naturally occurring retinal dystrophies are effect of gene dysfunction. recognised in other laboratory animals, for example the Royal College of Surgeons (RCS) Key words Animal model, cGMP rat which has been studied in detail, although phosphodiesterase, Peripherin / RDS; the responsible gene mutation currently Progressive retinal atrophy, Retinal dystrophy; remains elusive. Retinitis pigmentosa Companion animals, particularly dogs, represent a diverse source of different models of retinal dystrophies. The most important group Retinal dystrophies affect a number of different of conditions are the generalised progressive animal species and are well recognised in retinal atrophies (PRAs) (for a review see laboratory and companion animals. There are Petersen-Jones3). These inherited conditions all conditions of several species that mirror result in a progressive photoreceptor-led retinal conditions in man such as retinitis pigmentosa. degeneration resulting in similar clinical and Identification of the gene defects responsible for ophthalmoscopic signs, but with varying ages at two such mouse models of retinal dystrophy - onset and rates of progression. Those forms that dJ the retinal degeneration (rd, rdl or pdeb' ) have been studied in detail can be divided into S.M. Petersen-Jones � mouse and the retinal degeneration slow (rds, photoreceptor dysplasias or photoreceptor Department of Small Animal dZ Clinical Sciences rd2 or prph2, ) mouse - led to the screening of degenerations. With the dysplasias the College of Veterinary the same genes (the beta subunit of cyclic GMP photoreceptor development is abnormal or Medicine phosphodiesterase and peripherin/RDS becomes halted in the immediate postnatal Michigan State University respectively) in patients with retinal period when retinal maturation normally East Lansing MI48824-1314, USA dystrophies and resulted in the identification of occurs. The dysplastic photo receptors then Fax: +1 (517) 355-5164 a number of causal gene mutations. Some progressively degenerate. With those forms of 566 Eye (1998) 12, 566-570 © 1998 Royal College of Ophthalmologists PRA classified as degenerations the photoreceptors Retinal dystrophies of known genetic cause appear to attain normal adult conformation but The genetic causes of a number of retinal dystrophies subsequently progressively degenerate. PRA has been have been identified in man and fewer have been described in over 100 different breeds of dog, only a identified in animals. The following gives two examples small number of which have been studied in detail. where gene defects that are known to cause retinal Despite this, the breeding studies that have been dystrophies in man are also known to cause retinal performed have shown that there are several distinct dystrophies in animals. No doubt as further molecular forms of PRA. The majority of canine PRAs are studies of animal and human retinal dystrophies are recessively inherited although an X-linked form has been performed more animal homologues of human disease recognised in the Siberian husky and is the only animal will be identified. model of X-linked retinitis pigmentosa.4 One form, a progressive rod-cone degeneration (prcd), is present as an allelic condition in several breeds (miniature and toy poodle, English and American cocker spaniel, Labrador Cyclic GMP phosphodiesterase beta subunit (PDEj3) retriever and Portuguese water dog). Although the prcd mutations gene has not been identified, recently genetic linkage to The gene for PDEI), which encodes a member of the the locus was described.s Rod-cone dysplasia type one visual transduction cascade, is known to be mutated in (redl) in the Irish setter remains the only form of retinal dystrophies of man, mouse and dog. The first companion animal PRA for which the gene mutation has discovery of a mutation in these gene was in the retinal been identified (see Note added in proof). The mutation degeneration (rd) mouse. The rd mouse has a very early is in the cGMP phosphodiesterase beta subunit gene onset of photoreceptor disease. Photoreceptors develop (PDEI)). The same gene is mutated in the rd mouse and until about 10 days of age and then go on to degenerate also in some forms of retinitis pigmentosa as described in rapidly such that by 20 days of age most photoreceptors more detail in the following section. are lost (with the exception of some cones).16 Studies PRA is less common in the cat than the dog. Two have shown that there are elevations in retinal cGMP forms have been recognised and investigated in the levels prior to retinal degeneration,17 and that this is Abyssinian cat. One form, which has a very early onset associated with lowered cGMP phosphodiesterase and rapid progression, is dominantly inherited and is the activity.1S The defective gene was identified by Bowes et only companion animal model of autosomal dominant 1Y al. using a cDNA subtractive technique coupled with retinitis pigmentosa. The second form is recessively differential hybridisation?O,21 Two mutations were found inherited and has a later onset of a slow, progressive in the rd PDEI) gene. One is a nonsense mutation at rod-cone degeneration. This second form has similarities codon 34722 that introduces a stop codon; the second is a to prcd in the poodle. retroviral element inserted in intron 1.23 Both mutations As well as PRA the dog also suffers from another have been found in all strains of rd mice. Further group of progressive retinal diseases known as the confirmation that the mutant PDEI) gene was responsible retinal pigment epithelial dystrophies. In at least some of for rd was provided by introducing a normal copy of the the affected breeds there would appear to be an inherited gene into rd mice and showing that the resulting predisposition for the condition which is modified by an transgenic mice did not develop retinal degeneration.24 environmental factor.° Unlike PRA the primary lesion is The dog was the second animal species in which a in the retinal pigment epithelium and is associated with retinal dystrophy causing mutation of the PDEI) gene lipofuscin deposition? Cone dysplasia has also been was identified. A hereditary retinal degeneration had described in the dog, although it is very rare. A recent been recognised in the Irish setter breed of dog since the study of affected dogs showed an absence of cone outer 1930s and reached a very high incidence in show dogs segment beta 3-transducin immunoreactivity, making it a until a strict test-mating programme was introduced in candidate gene for the defect.8 Congenital stationary the 1940s and l%Os. This form of PRA is known as rod­ night blindness occurs in animals as well as humans. It is cone dysplasia type one (rcdl). Histopathological described in the Appaloosa horse9 although the genetic investigations showed that in rcdl the retina develops defect has not been identified. In man several forms of normally for the first 13 days of life after which CSNB are recognised and can result from mutations of photoreceptor differentiation becomes arrested?S the rod opsin,1O PDEI),l1 rhodopsin kinase,12 alpha-1 Biochemical analysis
Recommended publications
  • Retinitis Pigmentosa Precision Panel Overview Indications Clinical
    Retinitis Pigmentosa Precision Panel Overview Retinitis Pigmentosa (RP) comprises a complex group of inherited dystrophies characterized by degeneration and dysfunction of the retina, affecting photoreceptor and pigment epithelial function. RP can be an isolated finding or be part of a syndrome that can be inherited in a dominant, recessive or X-linked pattern. This disease presents as progressive loss of night and peripheral vision, leading to a constricted visual field and markedly diminished vision. The clinical presentation of these findings is highly variable, some patients being affected during childhood while others are asymptomatic well into adulthood. There is an increase in mortality rate due to psychiatric comorbidities. The Igenomix Retinitis Pigmentosa Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of blindness ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved. Indications The Igenomix Retinitis Pigmentosa Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: - Family history of RP - Night blindness - Progressive constriction of the visual field, usually peripheral - Cataracts - Sensation of sparking lights (photopsias) - Headache Clinical Utility The clinical utility of this panel is: - The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient. - Early initiation of multidisciplinary treatment in the form of medical care with vitamin A and other antioxidants and surgical care for potential cataract extraction or retinal prosthesis.
    [Show full text]
  • Optical Coherence Tomography
    Eponyms in Ophthalmology: What’s in a Name? What’s in a Name? How do ophthalmic diagnostic findings get their names? Timothy J. Bennett, CRA, OCT-C, FOPS Penn State Hershey Eye Center Hershey, PA SA-5-C What’s in a Name? What’s in a Name? Linnaean Taxonomy: system of Linnaean Taxonomy classification Binomial nomenclature Carl Linnaeus, 1707-1778 What About Human Anatomy? Anatomic Terminology In the late nineteenth century some Nomina Anatomica was the international 50,000 terms for various body parts standard on human anatomic terminology were in use. from 1956 until it was replaced by Terminologia Anatomica in 1998. The same structures were described by different names, depending on the anatomist’s background: school, language, culture, traditions, etc. 1 How About Ophthalmology? Diagnostic Naming Conventions Etymology: origins of words often from Greek or Latin roots Named for anatomic location Descriptive of process or result Descriptive of appearance Acronyms or initials Eponyms: named for first person to identify or describe Etymology Etymology Retinopathy from the Greek “Pathos”: suffering, disease, feeling, passion. Descriptive of Process or Result Descriptive of Process or Result Macular degeneration Vitreo-macular traction Plaquenil toxicity Macular hole 2 Descriptive of Appearance Descriptive of Appearance Literal Synonymous (looks like something else) Pink eye Cherry red spot Floppy lid syndrome Bear tracks Cataract? Ichthyosis Genetic skin disorder characterized by dry, scaly, or flaky skin that resembles
    [Show full text]
  • Assessing Retinal Structure in Complete Congenital Stationary Night Blindness and Oguchi Disease Pooja Godara Medical College of Wisconsin
    Marquette University e-Publications@Marquette Biomedical Engineering Faculty Research and Biomedical Engineering, Department of Publications 12-1-2012 Assessing Retinal Structure In Complete Congenital Stationary Night Blindness and Oguchi Disease Pooja Godara Medical College of Wisconsin Robert F. Cooper Marquette University Panagiotis I. Sergouniotis University College London Melissa A. Diederichs Medical College of Wisconsin Megan R. Streb University of Iowa See next page for additional authors NOTICE: this is the author’s version of a work that was accepted for publication in American Journal of Ophthalmology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in American Journal of Ophthalmology, Vol. 154, No. 6 (December 2012): 987–1001. DOI. © Elsevier 2012. Used with permission. Authors Pooja Godara, Robert F. Cooper, Panagiotis I. Sergouniotis, Melissa A. Diederichs, Megan R. Streb, Mohamed Genead, J. Jason McAnany, Andrew R. Webster, Anthony T. Moore, Adam M. Dubis, Maureen Neitz, Alfredo Dubra, Edwin M. Stone, Gerald A. Fishman, Dennis P. Han, Michel Michaelides, and Joseph Carroll This article is available at e-Publications@Marquette: https://epublications.marquette.edu/bioengin_fac/321 NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be accessed by following the link in the citation at the bottom of the page. Assessing Retinal Structure In Complete Congenital Stationary Night Blindness and Oguchi Disease Pooja Godara Department of Ophthalmology, Medical College of Wisconsin Milwaukee, WI Robert F.
    [Show full text]
  • Oguchi Disease with Unusual Findings Associated with A
    addition, the duration of treatment to induce retinal re- a golden-yellow discoloration of the fundus that disap- attachment is currently unknown. However, patients with pears after prolonged dark adaptation, called the Mizuo- IH have been treated for several months. Nakamura phenomenon. The International Society for Hemangiomas consist histologically of cavernous and Clinical Electrophysiology of Vision–protocol bright- capillary vascular networks. The mechanism by which flash electroretinograms (ERGs), performed after 30 min- oral propranolol aids in the resolution of exudative reti- utes of dark adaptation, are typically electronegative with nal detachment in DCH associated with Sturge-Weber a severely reduced b-wave and milder reduction of the syndrome is unknown. It is possible that, similar to IH, a-wave.1,2 After 3 to 4 hours of dark adaptation, both am- there is vasoconstriction of the DCH due to decreased plitudes recover to nearly normal, especially the a- release of nitric oxide, blocking of proangiogenic sig- wave.2 However, the recovered rod function is rapidly lost nals including vascular endothelial growth factor and ba- after a short light exposure or a single bright white flash.2,3 sic fibroblast growth factor, and apoptosis in proliferat- We describe a case of Oguchi disease with unusual find- ing endothelial cells with vascular tumor regression.5 ings caused by a putative heterozygous mutation in the To our knowledge, the benefits of propranolol therapy SAG gene. have not been reported in adult hemangioma or for DCH. This is the first reported case of propranolol treatment Report of a Case. A 40-year-old woman with visual acu- in an adult with exudative retinal detachment in DCH ity of 20/20 OU had fundus abnormalities and was re- associated with Sturge-Weber syndrome.
    [Show full text]
  • The Alter Retina: Alternative Splicing of Retinal Genes in Health and Disease
    International Journal of Molecular Sciences Review The Alter Retina: Alternative Splicing of Retinal Genes in Health and Disease Izarbe Aísa-Marín 1,2 , Rocío García-Arroyo 1,3 , Serena Mirra 1,2 and Gemma Marfany 1,2,3,* 1 Departament of Genetics, Microbiology and Statistics, Avda. Diagonal 643, Universitat de Barcelona, 08028 Barcelona, Spain; [email protected] (I.A.-M.); [email protected] (R.G.-A.); [email protected] (S.M.) 2 Centro de Investigación Biomédica en Red Enfermedades Raras (CIBERER), Instituto de Salud Carlos III (ISCIII), Universitat de Barcelona, 08028 Barcelona, Spain 3 Institute of Biomedicine (IBUB, IBUB-IRSJD), Universitat de Barcelona, 08028 Barcelona, Spain * Correspondence: [email protected] Abstract: Alternative splicing of mRNA is an essential mechanism to regulate and increase the diversity of the transcriptome and proteome. Alternative splicing frequently occurs in a tissue- or time-specific manner, contributing to differential gene expression between cell types during development. Neural tissues present extremely complex splicing programs and display the highest number of alternative splicing events. As an extension of the central nervous system, the retina constitutes an excellent system to illustrate the high diversity of neural transcripts. The retina expresses retinal specific splicing factors and produces a large number of alternative transcripts, including exclusive tissue-specific exons, which require an exquisite regulation. In fact, a current challenge in the genetic diagnosis of inherited retinal diseases stems from the lack of information regarding alternative splicing of retinal genes, as a considerable percentage of mutations alter splicing Citation: Aísa-Marín, I.; or the relative production of alternative transcripts. Modulation of alternative splicing in the retina García-Arroyo, R.; Mirra, S.; Marfany, is also instrumental in the design of novel therapeutic approaches for retinal dystrophies, since it G.
    [Show full text]
  • Mizuo-Nakamura Phenomenon in Oguchi Disease Due to A
    Correspondence 1098 lattice-like degeneration,4 non-neovascular vitreous haemorrhage,5 and myopia.4 Occasionally elevated blood vessels have been demonstrated secondary to vitreous traction.6 We postulate that in this case separation of intact retinal vascular arcades from the retina occurred because of antero–posterior mechanical forces on already dragged retinal vessels under tension when PVD occurred. Kingham also advocated conservative management for such cases. Conflict of interest The authors declare no conflict of interest. References 1 Shaikh S, Trese MT. New Insights into progressive visual loss in adult retinopathy of prematurity. Arch Ophthalmol 2004; 122(3): 404–406. 2 Tasman W. Vitreoretinal changes in cicatrical retrolental fibroplasias. Trans Am Ophthalmol soc 1970; 68: 548–594. 3 Kingham JD. Acute retrolental fibroplasia. II. Treatment by cryosurgery. Arch Ophthalmol 1978; 96(11): 2049–2053. 4 Smith BT, Tasman WS, Young TL, Wilson ME, Raab EL, Paysse EA et al. Retinopathy of prematurity: late complications in the baby boomer generation (1946–1964). Trans Am Ophthalmol Soc 2005; 103: 225–234. 5 Quiram PA, Capone Jr A. Adult ROP: late complications of retinopathy of prematurity. Retinal Physician 2007; 4(5): 25–28. 6 Tasman W, Brown GC. Progressive visual loss in adults with retinopathy of prematurity (ROP). Trans Am Ophthalmol Soc 1988; 86: 367–379. S Tarafdar, EE Obi and JR Murdoch Tennent Institute of Ophthalmology, Gartnavel Figure 1 (a) A nasally dragged disc and retinal vessels. (b) Intact General Hospital, Glasgow, Scotland, UK avulsed retinal vessels floating freely in the vitreous cavity. E-mail: [email protected] avulsed retinal vessels floating freely in the vitreous Eye (2011) 25, 1097–1098; doi:10.1038/eye.2011.86; cavity was present (Figure 1b).
    [Show full text]
  • Case Reports
    Open Access Case Report Oguchi Disease Pak Armed Forces Med J 2016; 66(6):933-34 CASE REPORTS OGUCHI DISEASE – TWO PATIENTS WITH VARIABLE GENE MUTATION AND OPTICAL COHERENCE TOMOGRAPHY FINDINGS Ahsan Mukhtar, Muhammad Saim Khan, Muhammad Tahir Armed Forces Institute of Ophthalmology/ National University of Medical Sciences (NUMS) Rawalpindi Pakistan ABSTRACT Oguchi disease is a rare form of congenital stationary night blindness which has autosomal recessive inheritance. It is characterized by typical clinical features in which there is golden yellow tapetal reflex over the fundus which disappears after prolonged dark adaptation. This clinical characteristic is known as "Mizuo-Nakamura phenomenon". Patients with Oguchi disease present with night blindness which is non-progressive and not associated with decreased vision, colour desaturation or visual field defects. We examined two patients who presented with night blindness since childhood. A 4 year boy and a 6 year old girl when examined in detail revealed Mizuo Nakamura phenomenon on fundus examination. They were further investigated with electrophysiological tests, optical coherence tomography and genetic studies to make a diagnosis of Oguchi`s disease. Keywords: Congenital stationary night blindness, Mizuonakamura phenomenon, Oguchi disease. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. INTRODUCTION years that was not associated with other ocular or Oguchi disease is a rare autosomal recessive systemic complaints. Visual acuity was 6/6 and form of congenital stationary night-blindness that posterior segment examination revealed an is characterized by a golden tapetal fundus reflex.
    [Show full text]
  • Congenital/Stationary Retinal Disease
    1 Congenital/Stationary Retinal Disease ? ? Two very basic categories 2 Congenital/Stationary Retinal Disease Cone (Color) Disease Rod (Night Vision) Disease Two very basic categories 3 Congenital/Stationary Retinal Disease Cone (Color) Disease Rod (Night Vision) Disease ? ? ? Three very basic categories 4 Congenital/Stationary Retinal Disease Cone (Color) Disease Rod (Night Vision) Disease Trichromatism Dichromatism Monochromatism Three very basic categories 5 Congenital/Stationary Retinal Disease Cone (Color) Disease Rod (Night Vision) Disease Trichromatism Dichromatism What doesMonochromatism it mean to say someone is a ‘trichromat’? It concerns performance on a color-matching test. In this test, the participant is askedRod to monochromatism match a test color by mixing primary-color lights (note--not mixing paints!). A trichromat requires three (hence the ‘tri-’) lights--one of short wavelength (aka blue), Blue-cone monochromatism one of medium wavelength (= green), and one of long (= red). (This is the normal state of color vision in humans.) 6 Congenital/Stationary Retinal Disease Cone (Color) Disease Rod (Night Vision) Disease Trichromatism Dichromatism What doesMonochromatism it mean to say someone is a ‘trichromat’? It concerns performance on a color-matching test. In this test, the participant is askedRod to monochromatism match a test color by mixing primary-color lights (note--not mixing paints!). A trichromat requires three (hence the ‘tri-’) lights--one of short wavelength (aka blue), Blue-cone monochromatism one of medium wavelength (= green), and one of long (= red). (This is the normal state of color vision in humans.) 7 Congenital/Stationary Retinal Disease Cone (Color) Disease Rod (Night Vision) Disease Trichromatism Dichromatism What doesMonochromatism it mean to say someone is a ‘trichromat’? It concerns performance on a color-matching test.
    [Show full text]
  • Retinal Imaging in Inherited Retinal Diseases
    20 Review Article Page 1 of 20 Retinal imaging in inherited retinal diseases Michalis Georgiou1,2, Kaoru Fujinami1,2,3, Michel Michaelides1,2 1UCL Institute of Ophthalmology, University College London, London, UK; 2Moorfields Eye Hospital NHS Foundation Trust, London, UK; 3Laboratory of Visual Physiology, Division of Vision Research, National Institute of Sensory Organs, National Hospital Organization Tokyo Medical Center, Tokyo, Japan Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Professor Michel Michaelides. UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK. Email: [email protected]. Abstract: Inherited retinal diseases (IRD) are a leading cause of blindness in the working age population. The advances in ocular genetics, retinal imaging and molecular biology, have conspired to create the ideal environment for establishing treatments for IRD, with the first approved gene therapy and the commencement of multiple therapy trials. The scope of this review is to familiarize clinicians and scientists with the current landscape of retinal imaging in IRD. Herein we present in a comprehensive and concise manner the imaging findings of: (I) macular dystrophies (MD) [Stargardt disease (ABCA4), X-linked retinoschisis
    [Show full text]
  • Blueprint Genetics Congenital Stationary Night Blindness Panel
    Congenital Stationary Night Blindness Panel Test code: OP1201 Is a 20 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion / diagnosis of congenital stationary night blindness. The genes on this panel are included in the Retinal Dystrophy Panel. About Congenital Stationary Night Blindness Congenital stationary night blindness (CSNB) is a non-progressive retinal disorder that is characterized by night or dim light vision disturbance or delayed dark adaptation, poor visual acuity (ranging from 20/30 to 20/200), myopia, nystagmus, strabismus, normal color vision and fundus abnormalities. CSNB can be subdivided according to the pattern of inheritance which may be X-linked, autosomal recessive or autosomal dominant. X-linked CSNB accounts for 57.9% of cases, autosomal recessive and sporadic CSNB account for 40% including 23.6% with a fundus abnormality, and the remaining 2.1% of cases have autosomal dominant CSNB. The incomplete form of X-linked CSNB (CSNB2) is caused by mutations in the CACNA1F gene and the complete form of X-linked CSNB (CSNB1) is due to defects in the NYX gene. Oguchi disease is a rare autosomal recessive form of CSNB associated with fundus discoloration and abnormally slow dark adaptation. Availability 4 weeks Gene Set Description Genes in the Congenital Stationary Night Blindness Panel and their clinical significance Gene Associated phenotypes Inheritance ClinVar HGMD CABP4 Night blindness, congenital stationary AR 6 11 CACNA1F Aland Island eye disease, Cone rod dystrophy,
    [Show full text]
  • A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina from Light Damage in Diverse Models of Night Blindness
    Physiology and Pharmacology A Mixture of U.S. Food and Drug Administration–Approved Monoaminergic Drugs Protects the Retina From Light Damage in Diverse Models of Night Blindness Henri Leinonen,1,2 Elliot H. Choi,1,2 Anthony Gardella,3 Vladimir J. Kefalov,4 and Krzysztof Palczewski1,2 1Gavin Herbert Eye Institute and the Department of Ophthalmology, University of California-Irvine, Irvine, California, United States 2Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States 3Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, Ohio, United States 4Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri, United States Correspondence: Krzysztof Palczewski, PURPOSE. The purpose of this study was to test the extent of light damage in different models Gavin Herbert Eye Institute, Depart- of night blindness and apply these paradigms in testing the therapeutic efficacy of ment of Ophthalmology, University of combination therapy by drugs acting on the Gi,Gs, and Gq protein-coupled receptors. California-Irvine, 850 Health Sciences Road, Irvine, CA 92697-4375, USA; METHODS. Acute bright light exposure was used to test susceptibility to light damage in mice [email protected]. lacking the following crucial phototransduction proteins: rod transducin (GNAT1), cone Submitted: January 3, 2019 transducin (GNAT2), visual arrestin 1 (ARR1), and rhodopsin kinase 1 (GRK1). Mice were Accepted: March 9, 2019 intraperitoneally injected with either vehicle or drug combination consisting of metoprolol (b1-receptor antagonist), bromocriptine (dopamine family-2 receptor agonist) and tamsulosin Citation: Leinonen H, Choi EH, Gar- (a -receptor antagonist) before bright light exposure. Light damage was primarily assessed della A, Kefalov VJ, Palczewski K.
    [Show full text]
  • Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss
    cells Review Mouse Models of Inherited Retinal Degeneration with Photoreceptor Cell Loss 1, 1, 1 1,2,3 1 Gayle B. Collin y, Navdeep Gogna y, Bo Chang , Nattaya Damkham , Jai Pinkney , Lillian F. Hyde 1, Lisa Stone 1 , Jürgen K. Naggert 1 , Patsy M. Nishina 1,* and Mark P. Krebs 1,* 1 The Jackson Laboratory, Bar Harbor, Maine, ME 04609, USA; [email protected] (G.B.C.); [email protected] (N.G.); [email protected] (B.C.); [email protected] (N.D.); [email protected] (J.P.); [email protected] (L.F.H.); [email protected] (L.S.); [email protected] (J.K.N.) 2 Department of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand 3 Siriraj Center of Excellence for Stem Cell Research, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand * Correspondence: [email protected] (P.M.N.); [email protected] (M.P.K.); Tel.: +1-207-2886-383 (P.M.N.); +1-207-2886-000 (M.P.K.) These authors contributed equally to this work. y Received: 29 February 2020; Accepted: 7 April 2020; Published: 10 April 2020 Abstract: Inherited retinal degeneration (RD) leads to the impairment or loss of vision in millions of individuals worldwide, most frequently due to the loss of photoreceptor (PR) cells. Animal models, particularly the laboratory mouse, have been used to understand the pathogenic mechanisms that underlie PR cell loss and to explore therapies that may prevent, delay, or reverse RD. Here, we reviewed entries in the Mouse Genome Informatics and PubMed databases to compile a comprehensive list of monogenic mouse models in which PR cell loss is demonstrated.
    [Show full text]